Scotiabank keeps Sector Outperform on Pfizer, sets $33 target
Scotiabank reiterated a Sector Outperform rating on Pfizer and maintained a $33.00 price target, implying 20.0% upside versus Pfizer’s Oct 6 close of $27.50.
Scotiabank reiterated a Sector Outperform rating on Pfizer and maintained a $33.00 price target, implying 20.0% upside versus Pfizer’s Oct 6 close of $27.50.